Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:11 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 929 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Stereotactic radiotherapy Clear all

Conditions: Non-small Cell Lung Cancer (NSCLC)
Interventions: Osimertinib, SABR; Drug · Radiation
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 99 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 2
States / cities: Duarte, California • Dallas, Texas

Conditions: Breast Cancer, Early-Stage Breast Carcinoma, Hormone Receptor-Positive Breast Cancer, HER2-Negative Breast Cancer
Interventions: Stereotactic Radiation Therapy, Endocrine Therapy; Radiation · Drug
Lead sponsor: Renaissance Institute of Precision Oncology and Radiosurgery; Other
Eligibility: 50 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2032
U.S. locations: 1
States / cities: Winter Park, Florida

Conditions: Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage IV
Interventions: Durvalumab, Tremelimumab, Stereotactic Body Radiotherapy; Drug · Radiation
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Unresectable Hepatocellular Carcinoma
Interventions: Atezolizumab, Bevacizumab, Stereotactic body radiation therapy (SBRT); Drug · Radiation
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Prostate Cancer
Interventions: 5 Gy x 5 fractions, 6 Gy x 5 fractions, 6.5 Gy x 5 fractions, maximum tolerated dose (6.5 Gy x 5 fractions), recommended phase 2 dose (6.5 Gy x 5 fractions); Radiation
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 90 Years · Male only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Brain Metastases
Interventions: Single Fraction Stereotactic Radiosurgery (SRS), Fractionated Whole Brain Radiation Therapy (WBRT), Fractionated Stereotactic Radiation Therapy (FSRT), Magnetic Resonance Imaging (MRI) Assessments; Radiation · Device
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2014
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Brain and Central Nervous System Tumors, Metastatic Cancer, Radiation Toxicity
Interventions: Questionnaire; Other
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Malignant Neoplasms
Interventions: SCART radiation therapy; Radiation
Lead sponsor: Baptist Health, Louisville; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 3
States / cities: Miami, Florida • Corbin, Kentucky • Morehead, Kentucky

Conditions: Non-small-cell Lung Cancer
Interventions: SBRT (stereotactic body radiotherapy), SBPT (stereotactic body proton therapy); Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Glioblastoma Multiforme
Interventions: MBG453; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 2
States / cities: Stanford, California • Baltimore, Maryland

Conditions: Non-small Cell Lung Cancer Stage I
Interventions: Ad5-yCD/mutTKSR39rep-ADP Adenovirus; Biological
Lead sponsor: Benjamin Movsas, M.D.; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Prostatic Neoplasms, Prostate Cancer
Interventions: CDX1127, SBRT; Biological · Radiation
Lead sponsor: James Larner, MD; Other
Eligibility: 18 Years and older · Male only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Recurrent Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lymph Nodes, Oligometastasis, Prostate Adenocarcinoma, PSA Failure
Interventions: Hypofractionated Radiation Therapy, Intensity-Modulated Radiation Therapy, Metastasectomy, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy; Radiation · Procedure · Other
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Spinal Metastases, Vertebral Metastases, Benign Spinal Tumors, Chordoma, Meningioma, Schwannoma, Neurofibroma, Paragangliomas, Arteriovenous Malformations
Interventions: SBRT for Benign Extradural Spine Tumors, SBRT for Vertebral/Paraspinal Metastases; Radiation
Lead sponsor: Mercy Research; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2017
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Non-small Cell Lung Cancer, Lung Cancer, NSCLC
Interventions: Stereotactic boost, Conventional RT, Etoposide, Cisplatin; Radiation · Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Non-small Cell Lung Cancer
Interventions: Induction chemotherapy and concurrent radiation, Consolidation: Radiation therapy to metastatic sites; Other
Lead sponsor: Leo W. Jenkins Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Greenville, North Carolina

Conditions: Lung Carcinoma, Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Lung
Interventions: Artificial Intelligence-based Intervention, Best Practice, Computed Tomography, Positron Emission Tomography, Radiology, Treatment Planning, Stereotactic Body Radiation Therapy, Survey Administration; Other · Procedure · Radiation
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2032
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Tachycardia, Ventricular
Interventions: Varian Cardiac Radioablation (CRA), Catheter Ablation (CA); Device · Procedure
Lead sponsor: Varian, a Siemens Healthineers Company; Industry
Eligibility: 18 Years and older
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 12
States / cities: Los Angeles, California • Hartford, Connecticut • New Haven, Connecticut + 9 more

Conditions: Epidural Spinal Tumors, Cancer
Interventions: Pembrolizumab, Stereotactic Body Radiation Therapy, Blood draws; Drug · Radiation · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Solid Tumor, Metastatic Solid Tumor, Solid Carcinoma, Solid Tumor, Adult, Metastatic Tumor, Metastatic Cancer
Interventions: AZD1390, Stereotactic Body Radiotherapy; Drug · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 5
States / cities: Middletown, New Jersey • Commack, New York • Harrison, New York + 2 more

Conditions: Pancreatic Cancer, Pancreatic Adenocarcinoma
Interventions: Stereotactic Body Radiation Therapy (SBRT), FOLFIRINOX; Radiation · Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Vertebral Metastasis
Interventions: Stereotactic Radiation Therapy, SRT with Vertebral Augmentation Procedure; Radiation
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Lung Cancer
Interventions: computed tomography, fludeoxyglucose F 18, hypofractionated radiation therapy, stereotactic radiosurgery; Procedure · Radiation
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Prostate Cancer
Interventions: stereotactic body radiotherapy; Radiation
Lead sponsor: Mercy Research; Other
Eligibility: 18 Years and older · Male only
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 1
States / cities: St Louis, Missouri

Search by objective public record fields.

Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC

SOLIS: Single-Dose Radiotherapy With Omission of Lumpectomy for Intact Small Breast Cancers

Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition

Atezolizumab+Bevacizumab+SBRT in Unresectable HCC

PRE-ProstAtectomy MRI-GuidEd Stereotactic Body RadioTherapy for High-Risk Prostate Cancer Trial (PREPARE SBRT)

MRI Study of Changes in Blood-Brain/Tumor-Barrier Permeability in Patients With Brain Metastases During and After Radiotherapy

Acute Side Effects in Patients Who Are Undergoing Stereotactic Radiosurgery for Brain Tumors or Other Brain Disorders

A Phase I Study Evaluating the Safety of Stereotactic Central Ablative Radiation Therapy (SCART) for Bulky Metastatic or Recurrent Cancer

Stereotactic Body Radiotherapy (SBRT) Versus Stereotactic Body Proton Therapy (SBPT)

Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM

Oncolytic Adenovirus-Mediated Gene Therapy for Lung Cancer

Pilot Study of SBRT and CDX-1127 in Prostate Cancer

Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate Cancer

Stereotactic Body Radiotherapy for Spine Tumors

Stereotactic Boost for Locally Advanced Non-Small Cell Lung Cancer

Treating NSCLC Minimal Stage IV With Curative Intent

Using an Artificial Intelligence Software Tool (iSeg) During Radiation Treatment Planning for Patients With Lung Tumors

Cardiac RADIoablation Versus Repeat Catheter Ablation: a Pivotal Randomized Clinical Trial Evaluating Safety and Efficacy for Patients With High-risk Refractory Ventricular Tachycardia (RADIATE-VT)

Study of Combined Decompressive Spine Radiosurgery and Pembrolizumab

A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer

Study of Neoadjuvent Chemotherapy Followed by SBRT in Patients With Resectable and Borderline Resectable Pancreatic Cancer

Phase II Trial of Stereotactic Radiation Therapy (SRT) Versus SRT Plus Vertebral Augmentation Procedure (VAP) for Vertebral Metastasis

Stereotactic Radiosurgery in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer

Stereotactic Body Radiotherapy for Prostate Cancer